Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2V617F‐Positive Myeloproliferative Neoplasms

ABSTRACT Background The incidence, outcomes and risk factors for AF in the JAK2V617F‐positive MPN patients are still unknown. Methods The clinical profiles of patients with JAK2V617F‐positive MPN were retrospectively analyzed. Multivariable Cox regression analysis was performed to identify risk fact...

Full description

Saved in:
Bibliographic Details
Main Authors: Guangshuai Teng, Ke Shang, Yuhui Zhang, Yifan Duan, Chenxiao Du, Yan Wang, Yanqi Li, Huiqin Zhang, Lan Peng, Xiaojing Wei, Gary Tse, Yuan Zhou, Gregory Y. H. Lip, Tong Liu, Wei Yang, Minghui Duan, Jie Bai
Format: Article
Language:English
Published: Wiley 2025-07-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.71015
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Background The incidence, outcomes and risk factors for AF in the JAK2V617F‐positive MPN patients are still unknown. Methods The clinical profiles of patients with JAK2V617F‐positive MPN were retrospectively analyzed. Multivariable Cox regression analysis was performed to identify risk factors of AF, thereby developing a risk prediction model. Results A total of 439 patients were included (age 57 [12–87] years; 51.3% male). AF was associated with higher risks of stroke (p = 0.036, HR = 1.987, 95% CI 1.047–3.772) and mortality (p < 0.001, HR = 3.857, 95% CI 1.836–8.103). Multivariable Cox regression showed that TET2 mutation (p = 0.042, HR = 4.361, 95% CI 1.053–18.056) and increased IL‐1β (p = 0.012, HR = 5.476, 95% CI 1.547–28.123) were significant risk factors for AF in patients with JAK2V617F‐positive MPN. Nomograms were constructed, allowing patients to be categorized into high‐ and low‐risk groups. The 10‐year AF‐free survival rate was significantly lower in the high‐risk group (62% vs. 91.7%; log‐rank test: p = 0.002). The validation cohort confirmed that the survival without AF in the high‐risk group was significantly worse than that in the low‐risk group. The use of either interferon‐α or ruxolitinib, was associated with longer AF‐free survival in the high‐risk group (p < 0.05). Conclusion AF was significantly associated with higher risks of stroke and mortality. TET2 mutation and increased IL‐1β were independent risk factors of AF in patients with JAK2V617F‐positive MPN.
ISSN:2045-7634